<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288547</url>
  </required_header>
  <id_info>
    <org_study_id>07045V</org_study_id>
    <nct_id>NCT01288547</nct_id>
  </id_info>
  <brief_title>Effects of Theobromine and Caffeine on Mood, Cognition and Blood Pressure</brief_title>
  <official_title>Temporal Change of Mood and Cognition in Healthy Subjects After Consumption of Theobromine and/ or Caffeine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to measure potential mood, cognition and blood pressure effects&#xD;
      of theobromine and caffeine in healthy women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Previous research has shown that naturally occurring chocolate ingredients&#xD;
      theobromine and caffeine have positive effects on mood.&#xD;
&#xD;
      Objectives: To assess mood and cognition in adult subjects after the consumption of capsules&#xD;
      filled with 1. placebo, 2. theobromine alone, 3. caffeine alone or, 4. theobromine and&#xD;
      caffeine combined together.&#xD;
&#xD;
      Study design: Double-blind, placebo-controlled, randomized, cross-over design, with a 1 week&#xD;
      washout period in between.&#xD;
&#xD;
      During the 4 weeks intervention period, once a week one of the 4 types of test products were&#xD;
      consumed with 250ml of water in a randomized order;&#xD;
&#xD;
        1. placebo capsules&#xD;
&#xD;
        2. theobromine capsules (700 mg),&#xD;
&#xD;
        3. caffeine capsules (120 mg),&#xD;
&#xD;
        4. mix of theobromine (700 mg) and caffeine (120 mg). Twenty-four healthy female subjects&#xD;
           (and 4 reserve subjects) were recruited for a four week intervention period in total&#xD;
           with every week a 4 hrs measurement day and one of the interventions.&#xD;
&#xD;
      Primary parameters: mood (via a Bond-Lader/ caffeine visual analogue questionnaire),&#xD;
      cognition (Digit Symbol substitution) Secondary parameters: blood pressure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood and cognition</measure>
    <time_frame>3 hrs every week for 4 weeks</time_frame>
    <description>Bond Lader Visual Analogue Scale&#xD;
Digit Symbol Substitution&#xD;
Caffeine Negative Symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure and heart rate</measure>
    <time_frame>3 hrs every week for 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Mood</condition>
  <arm_group>
    <arm_group_label>theobromine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>theobromine (700 mg) in capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>caffeine (120 mg) in capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no theobromine or caffeine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>theobromine + caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>theobromine</intervention_name>
    <description>700 mg theobromine in gelatin capsules given one time only</description>
    <arm_group_label>theobromine</arm_group_label>
    <other_name>3,7-dimethylxanthine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>120 mg caffeine in capsules given one time only</description>
    <arm_group_label>caffeine</arm_group_label>
    <other_name>1,3,7-trimethylxanthine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>caffeine + theobromine</intervention_name>
    <description>120 mg caffeine and 700 mg theobromine in capsules given one time only</description>
    <arm_group_label>theobromine + caffeine</arm_group_label>
    <other_name>methylxanthines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>cellulose in capsules given one time only</description>
    <arm_group_label>Placebo capsule</arm_group_label>
    <other_name>avicel (cellulose)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age at start of study 18 till 70 years&#xD;
&#xD;
          -  Body Mass Index (BMI) between 20 and 30 kg/m2 inclusive&#xD;
&#xD;
          -  Reported alcohol consumption for females &lt; 21&#xD;
&#xD;
          -  Willing to refrain from caffeine and theobromine for 24 hours&#xD;
&#xD;
          -  Apparently healthy: no reported current or previous metabolic diseases, chronic&#xD;
             gastrointestinal disorders, cardiovascular or psychiatric disease which might effect&#xD;
             study measurements assessed by Research physician&#xD;
&#xD;
          -  willing to consume animal foods products (gelatine).&#xD;
&#xD;
          -  Consumes caffeine (7 cups of either tea, cola or coffee per week minimum)&#xD;
&#xD;
          -  Having a general practitioner (GP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being an Unilever employee&#xD;
&#xD;
          -  Blood pressure above 160/90 mmHg at screening and irregular heart rate&#xD;
&#xD;
          -  Using or planning to use any medically prescribed diet or weight-loss diet&#xD;
&#xD;
          -  Reported intense sporting activities &gt; 10 h/w&#xD;
&#xD;
          -  Subjects who undergoing medical treatment that may interfere with the study outcome.&#xD;
&#xD;
          -  Reported weight change Â± 10% during a period of 6 months prior to the study&#xD;
&#xD;
          -  Reported intolerance or allergy for one of test products or standardized meal&#xD;
&#xD;
          -  The habit of smoking during the past half year, drug use during the past half year or&#xD;
             using nicotine containing medicines during the past month&#xD;
&#xD;
          -  Reported lactating (or lactating &lt; 6 weeks ago), pregnant (or pregnant &lt; 3 months ago)&#xD;
             or wish to become pregnant during the study&#xD;
&#xD;
          -  Not able to perform the computer tasks assessed during screening&#xD;
&#xD;
          -  Reported participation in night shift work during the study period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Zebregs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unilever R&amp;D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unilever Discover</name>
      <address>
        <city>Vlaardingen</city>
        <state>Zuid Holland</state>
        <zip>3130 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognition</keyword>
  <keyword>attention</keyword>
  <keyword>methylxanthine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theobromine</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

